Journal of Medicinal Chemistry · 1997 · 153 citations · 50 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsAnti-inflammatory PharmacologyEnzyme InhibitionInflammation PharmacologyStructure-activity Relationship AnalysisAnti-inflammatory Drug DiscoveryAnti-inflammatory TherapeuticsCyclooxygenase InhibitorsCyclooxygenase TargetsCyclooxygenase-2 PathwayImidazole ChemistryNonsteroidal Anti-inflammatory Drug PharmacologySelective Cyclooxygenase-2 Inhibitors
Series of 1,2-diarylimidazoles has been synthesized and found to contain highly potent and selective inhibitors of the human COX-2 enzyme. The paper describes a short synthesis of the target 1,2-diarylimidazoles starting with aryl nitriles. Different portions of the diarylimidazole (I) were modified to establish SAR. Systematic variations of the substituents in the aryl ring B have yielded very potent (IC50 = 10-100 nm) and selective (1000-12500) inhibitors of the COX-2 enzyme. The study on the influence of substituents in the imidazole ring established that a CF3 group at position 4 gives the optimum oral activity. A number of the diarylimidazoles showed excellent inhibition in the adjuvant induced arthritis model (e.g., ED50 = 0.02 mpk for 22 and 34). The diarylimidazoles are also potent inhibitors of carrageenan-induced edema (ED50 = 9-30 mpk) and hyperalgesia (ED50 = 11-40 mpk). Several orally active diarylimidazoles show no GI toxicity in the rat and mouse up to 200 mpk.
50
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Robert C. Hastings · JAMA · 1996 · 2.4K citations
Thomas D. Penning, John J. Talley, Stephen R. Bertenshaw et al. · Journal of Medicinal Chemistry · 1997 · 2K citations · Full text
Dean A. Kujubu, Bradley S. Fletcher, Brian Varnum et al. · Journal of Biological Chemistry · 1991 · 1.8K citations · Full text